Scholarlink

<p>Routine annual vaccination remains the most effective way to prevent infection caused by the influenza virus. Inactivated egg-based vaccines are the established standard. Recent development including cell-based, high dose, adjuvanted, and recombinant vaccines has provided incremental improvements in vaccine efficacy. Live-attenuated vaccines may have advantages, although are not recommended for high-risk patients. Further vaccine technologies are in clinical development, including vaccine platforms used during the COVID-19 pandemic. New research is required to accurately predict real-world efficacy of enhanced vaccines that activate non-haemagglutinin immune responses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Use standard and enhanced vaccines to prevent influenza, while new classes remain in development

  • 期刊论文

  • 发表日期：

    2025年5月16日

查看全文
  • Michael B. Brown

摘要

Routine annual vaccination remains the most effective way to prevent infection caused by the influenza virus. Inactivated egg-based vaccines are the established standard. Recent development including cell-based, high dose, adjuvanted, and recombinant vaccines has provided incremental improvements in vaccine efficacy. Live-attenuated vaccines may have advantages, although are not recommended for high-risk patients. Further vaccine technologies are in clinical development, including vaccine platforms used during the COVID-19 pandemic. New research is required to accurately predict real-world efficacy of enhanced vaccines that activate non-haemagglutinin immune responses.